Managing diabetes with nanomedicine: challenges and opportunities by Langer, Robert S et al.
Managing diabetes with nanomedicine: challenges and 
opportunities
Omid Veiseh1,2,3,*, Benjamin C. Tang2,3,*, Kathryn A. Whitehead4, Daniel G. 
Anderson1,2,3,5,6, and Robert Langer1,2,3,5,6
1Department of Chemical Engineering, Massachusetts Institute of Technology, 77 Massachusetts 
Ave., Cambridge, Massachusetts 02139, USA
2David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 
77 Massachusetts Ave., Cambridge, Massachusetts 02139, USA
3Department of Anesthesiology, Boston Children’s Hospital, 300 Longwood Ave., Boston, 
Massachusetts 02115, USA
4Department of Chemical Engineering, Carnegie Mellon University, 5000 Forbes Ave., Pittsburgh, 
Pennsylvania 15213, USA
5Division of Health Science and Technology, Massachusetts Institute of Technology, Cambridge, 
Massachusetts 02139, USA
6Institute for Medical Engineering and Science, Massachusetts Institute of Technology, 
Cambridge, Massachusetts 02139, USA
Abstract
Nanotechnology-based approaches hold substantial potential for improving the care of patients 
with diabetes. Nanoparticles are being developed as imaging contrast agents to assist in the early 
diagnosis of type 1 diabetes. Glucose nanosensors are being incorporated in implantable devices 
that enable more accurate and patient-friendly real-time tracking of blood glucose levels, and are 
also providing the basis for glucose-responsive nanoparticles that better mimic the body’s 
physiological needs for insulin. Finally, nanotechnology is being used in non-invasive approaches 
to insulin delivery and to engineer more effective vaccine, cell and gene therapies for type 1 
diabetes. Here, we analyse the current state of these approaches and discuss key issues for their 
translation to clinical practice.
Diabetes mellitus is defined as a group of metabolic disorders characterized by high blood 
glucose levels (hyperglycaemia)1. The incidence of diabetes is rising; the number of affected 
patients worldwide is expected to increase from over 280 million adults today to over 400 
million adults by 2030 (REF. 2). The total annual global costs associated with the treatment 
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of diabetes and its complications amount to US$500 billion3, not including indirect costs 
associated with lost work time.
Type 1 diabetes, also known as juvenile diabetes, accounts for 10% of all diabetes mellitus 
cases4. It results from a deficiency in insulin — a 51-amino-acid peptide produced by the β-
cells of the islets of Langerhans in the pancreas — which regulates blood glucose levels by 
stimulating liver and muscle cells to take up glucose from the blood4. This deficiency stems 
from an autoimmune response in affected individuals that leads to the T-cell-mediated 
destruction of β-cells and subsequent hypoinsulinaemia and hyperglycaemia5. Type 2 
diabetes, unlike type 1 diabetes, is often categorized as a ‘lifestyle disease’6, and is 
associated with obesity and a lack of physical activity. Patients with type 2 diabetes develop 
insulin resistance — that is, their response to insulin produced by β-cells (for example, after 
a meal) is blunted, again leading to hyperglycaemia7.
Persistent glycaemic control is a key determinant of long-term outcomes for patients with 
diabetes8. The goal of management for both type 1 and type 2 diabetes is the maintenance of 
blood glucose levels within healthy normoglycaemic ranges (70–140 mg per dl or 4–8 mM; 
known as euglycaemia)9. When left untreated, prolonged hyperglycaemia can lead to 
blindness, kidney and heart disease, nerve degeneration and increased susceptibility to 
infection10. Conversely, insulin overtreatment may cause hypoglycaemia, which can lead to 
seizures, unconsciousness or death11.
For type 1 diabetes patients, insulin replacement therapy is prescribed with the goal of 
mimicking natural fluctuations in insulin levels throughout the day12. Typical treatment 
includes injections of long-acting insulin (with a longer plasma half-life than regular insulin) 
to provide a basal level of insulin, which is supplemented with bolus injections of fast-acting 
insulin (with a shorter plasma half-life) at mealtimes12,13. For type 2 diabetes, initial 
treatment focuses on delaying disease progression through exercise and regulation of 
meals1. Patients also receive oral and/or injectable medication that improves insulin 
production and function6. However, insulin replacement therapy is often ultimately required 
as native insulin production diminishes9.
Owing to the harsh environment of the gastrointestinal tract, insulin and other 
macromolecular diabetic therapies (that is, glucagon-like peptide 1) must be injected 
subcutaneously, which can be painful and inconvenient, leading to poor patient 
compliance14. Moreover, this conventional form of insulin replacement therapy is ‘open 
loop’, meaning that it relies on a historical understanding of the patient’s unique blood 
glucose profile in response to various meals and insulin treatments to determine insulin 
dosages8. Several technologies have been developed to overcome the drawbacks of injection 
therapy by dynamically controlling insulin levels with real-time data, while reducing the 
patient burden associated with treatment (BOX 1). These technologies include both insulin 
pumps and continuous glucose monitors15. One notable example is the dual hormone 
(insulin and glucagon) bionic pancreas glycaemic control system, which was recently 
evaluated in a Phase II trial in patients with type 1 diabetes16. This system was shown to 
significantly improve glycaemic control while reducing the frequency of hypoglycaemic 
episodes16.
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Box 1
Improved technologies for insulin replacement therapy
For patients with diabetes mellitus, traditional insulin replacement therapy can be painful 
and time consuming177. In addition, the lag between glucose measurement and insulin 
dosing, combined with delayed absorption of insulin following subcutaneous injection, 
limits tight blood glucose control and can lead to periods of hyperglycaemia (see the 
figure).
Several technologies have been developed to improve patient compliance associated with 
insulin replacement therapy, while also improving the dynamic control of blood glucose 
levels. For example, externally worn pager-sized insulin pumps have been developed that 
contain a replaceable depot of insulin connected to a subcutaneously implanted cannula. 
The pager can be programmed to deliver a basal level of insulin throughout the day as 
well as bolus insulin dosages on demand for meals through continuous insulin infusion. 
Alternatively, continuous glucose monitors (CGMs) are externally carried portable 
devices that provide near real-time measurements of blood glucose without the pain of 
repeated finger pricks13,178. Sensors are inserted subcutaneously and measure glucose 
levels in the interstitial fluid, which provides an estimate for blood glucose levels.
Most recently, microcomputer-controlled closed loop insulin delivery systems are being 
developed, where CGMs are used in conjunction with insulin pumps to automatically 
calculate and inject appropriate doses of insulin179,180. The goal of this technology is to 
provide a ‘patient intervention-free’ insulin replacement therapy. Here, the CGMs are 
linked directly, and are used in conjunction with insulin pumps to automatically calculate 
and inject appropriate doses of insulin179,180. Although these closed loop systems 
improve on glucose control, they do not achieve true euglycaemia as glucose levels are 
measured in the interstitial fluid and insulin is injected subcutaneously, which both 
present a time delay in diffusing to and from the bloodstream. Appropriate safety 
mechanisms are critical in closed loop systems such as these to prevent insulin overdose, 
which can lead to fatal hypoglycaemia.
Even with these technologies to improve patient compliance and glucose control, there 
are still major drawbacks. Insulin pumps and CGMs are expensive, and implanted 
sensors and cannulas increase the patient’s risk of infection, inflammation and 
scarring8,15, and they also require frequent maintenance and replacement owing to the 
foreign body response, increasing effort and cost to patients8.
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Despite these technological advances, it remains difficult to maintain ideal glucose levels 
using insulin replacement therapy in the vast majority of patients15 (BOX 1). A retrospective 
study of patients with diabetes estimated that ~50% of patients do not achieve their target 
glycaemic levels throughout the day17. Contributing factors include: the open-loop nature of 
current therapies, whereby insulin is injected into the subcutaneous space (as opposed to the 
portal blood where insulin is secreted from the pancreas); approximating subcutaneous fluid 
as having the same glucose concentration as blood; and poor patient compliance1. To 
provide clinical improvements, future therapies need to be easier to use while achieving 
tighter glycaemic control, better safety profiles and, ideally, a reduced cost to manufacture 
and implement into clinical practice15. Towards these goals, scientists are working to enable 
alternative routes of insulin administration18, optimize insulin pharmacokinetics12 and 
develop new therapeutic entities19.
Over the past 20 years, nanotechnology has improved both diagnostics and therapeutics in 
several medical fields, including oncology and cardiology20–23. Indeed, nanoparticles and 
nanoscaled materials have many physical, chemical and biological properties that render 
them attractive for biomedical applications21,24. Nanoparticles are used to deliver both 
small-molecule and large macromolecular (that is, DNA, RNA and proteins) therapeutics, as 
well as to diagnose and monitor the progression of disease25. A myriad of novel 
nanoparticle formulations with varying architectures have been fabricated for biomedical 
applications, including liposomes, polymer nanoparticles, nanostructures, metallic 
nanoparticles, stimuli-responsive nanoparticles and nanofabricated devices26–33. Here, we 
review the developing role of nanotechnology in diabetes management34, from diagnosis 
and disease monitoring to therapeutics (FIG. 1). We focus on the most mature technologies 
in each category that we feel are most likely to have an impact on the treatment of diabetes 
in the near future.
Diagnosis and disease monitoring
Advances in nanotechnology, molecular imaging and biomedical imaging tools are creating 
new opportunities for early diagnosis, staging and monitoring of disease progression for 
patients with type 1 or type 2 diabetes35. Early detection of diabetes and identification of 
disease progression are important aspects of disease management35. For example, as 
diabetes progresses, there is a reduction in β-cell mass and its respective insulin production 
and secretion36. Although the quantification of functional β-cells may enable physicians to 
prescribe more successful therapies and allow scientists to develop improved β-cell-targeted 
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therapies, direct measurement of β-cell mass is impractical as it requires post-mortem 
autopsy. In recent years, opportunities to assess β-cell mass using imaging have evolved 
with the development of β-cell-targeting peptide dyes37 and antibody–dye conjugates38, but 
these are generally reserved to excised tissue samples requiring invasive procedures. 
Alternatively, nanoprobes are being developed with β-cell specificity and high contrast39, 
which may enable clinicians and researchers to non-invasively quantify in vivo endogenous 
β-cell mass40, survival of exogenous transplanted islets41 and the performance of islet cells 
in cell replacement therapy42–46. Various non-invasive imaging techniques are being 
investigated for the visualization of β-cell mass, including computed tomography (CT), 
positron emission tomography (PET) and magnetic resonance imaging (MRI)47.
Several magnetic nanoparticle probes have been developed as contrast agents for β-cell 
imaging46,48. In particular, superparamagnetic iron oxide nanoparticles (SPIONs) are 
attractive in that they are biocompatible and can degrade into iron and oxygen31. The 
superparamagnetic properties enable these nanoparticles to be targeted using magnetism, 
tracked using MRI and used as magnetic triggers for drug release20,49. SPIONs have been 
developed to monitor immune cell infiltration and subsequent pancreatitis as an early 
detection tool for diagnosing diabetes42. In a pilot clinical study, non-diabetic healthy 
volunteers and patients with recent-onset diabetes were infused with a clinically approved 
SPION-based MRI contrast-imaging agent, ferumoxtran-10 — a dextran-coated iron oxide 
nanoparticle that, owing to its size and surface properties, is readily taken up by 
macrophages — and scanned using a 1.5T clinical MRI instrument to monitor pancreatitis50. 
The study enabled visualization of the pancreas and, more importantly, demonstrated a 
twofold difference in the T2 relaxation time of the pancreas in diabetic patients versus 
healthy volunteers owing to ongoing islet inflammation50.
The direct imaging of β-cell mass via iron oxide nanoparticles can also be used to monitor 
endogenous and exogenously transplanted islet cells45. Ferrimagnetic iron oxide nanocubes 
possess high relaxivity, which increases MRI resolution, allowing the visualization of single 
cells in pancreatic islets using a clinical MRI instrument44. Although major advances have 
been made in the development of imaging probes for monitoring inflammation and β-cell 
biomass, a need remains for molecularly targeted probes that can report directly on islet 
functionality in vivo. Specifically, the development of unique biomarkers that are specific 
for the β-cell surface and can monitor β-cell stress or dysfunction could help accelerate the 
clinical assessment of therapies to promote β-cell health and survival, as well as the 
stratification of patients by disease status for targeted therapies.
Glucose sensors
Frequent monitoring of blood glucose levels provides patients and physicians with an 
understanding of diabetes progression and the efficacy of therapies13. A number of 
technologies are currently available that facilitate outpatient self-administered blood glucose 
testing51. Unfortunately, lag times, lack of precision and difficulty with patient use remain 
major challenges (BOX 2). Furthermore, recent guidelines published by the US Food and 
Drug Administration (FDA) indicate that more stringent accuracy and reliability 
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requirements will be imposed in the near future for glucose sensors52. Nanotechnology has 
the potential to enable the development of improved sensors.
Box 2
Current glucose sensors and future goals
Currently, most patients with diabetes depend on handheld glucometers for monitoring 
glycaemic levels181. These devices rely on a single sampling of blood collected through 
finger pricks and are typically used only a few times a day (on average four to six times a 
day)1. Continuous glucose monitors (CGMs), which are subcutaneously implanted 
amperometric sensors (typically inserted into the fatty layer of abdominal skin) that emit 
an electrical current in response to glucose oxidation, continually sample interstitial 
fluid51. Unfortunately, current versions of CGMs produce measurements that lag 5 15 
minutes behind blood glucose levels owing to the diffusion of glucose from the blood to 
the interstitial fluid180. Additional drawbacks that have limited their widespread use 
include the invasive implantation procedure, the frequent need for replacement because 
of fouling and sensor instability, and a requirement to calibrate the sensor numerous 
times throughout the day using handheld glucometers180. Next-generation sensors will 
need to provide high accuracy for prolonged periods while being patient-friendly.
In general, sensing devices are constructed by assembling three key components: a detector 
that measures blood glucose concentrations; a transducer that converts measurements into 
output signals; and a reporter that processes the generated signal into data that can then be 
interpreted by the patient or physician. There are three main classes of glucose-sensing 
molecules that are being used to engineer nanoparticle-based glucose sensors. These include 
glucose oxidase, glucose-binding proteins and glucose-binding small molecules (FIG. 2a). 
When coupled with nanoparticles engineered as transducers, these glucose-specific detecting 
molecules are enabling the design of new types of sensors that have the potential to be more 
patient-friendly, provide rapid measurements and improve precision53 (FIG. 2b).
The first generation of glucose nanosensors utilize the amperometric glucose oxidase-
sensing technology as traditional blood glucose sensors54. Glucose oxidase possesses a high 
level of specificity for glucose, and reacts under biological environments (that is, in blood 
and urine) to enzymatically convert glucose into D-glucono-δ-lactone (which hydrolyses 
into gluconic acid) and hydrogen peroxide55 (FIG. 2a). The oxidation results in an electric 
current that is proportional to glucose concentration56. Nanosensors containing glucose 
oxidase have been built onto the surface of metallic nanoparticles, including palladium, gold 
and platinum nanoparticles, as well as carbon nanotubes57–59. The optimal material remains 
unclear as each has its unique advantages, such as stability and ease of manipulation, and its 
limitations, such as long-term accumulation and biocompatibility. Glucose oxidase-based 
approaches have one inherent disadvantage, in that glucose oxidase can have considerable 
batch-to-batch variability in activity, and its activity can diminish over time56,60. It also 
requires a constant oxygen level, pH and temperature, as well as frequent recalibration for a 
reliable readout55.
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To address the limitations of glucose oxidase, non-enzymatic nanosensors have been 
developed to improve reliability through the elimination of drift — the continuous decrease 
in output signal in relation to glucose concentration caused by enzyme degradation and loss 
of activity — and inconsistent enzyme activity61–63. One type of non-enzymatic glucose 
sensors function by oxidising glucose using a metal oxide catalyst such as copper oxide62,64 
or gold nanoparticles61. This ampero-metric approach with oxidation-based sensors involves 
the use of an applied voltage to drive the reaction; a battery and a device is required to 
measure the resulting current, making it less convenient for the patient owing to the 
increased size of the sensor.
Another non-enzymatic approach is based on the binding of glucose to the sensor to provide 
a fluorescent65 or voltammetric readout53. Transcutaneous fluorescence-based glucose 
sensors are currently being evaluated in clinical trials, and early data suggest that this 
technique can produce a reliable output for tracking blood glucose levels66. In these devices, 
when glucose displaces water in a binding pocket on the sensor, there is a shift in electron 
density that can be measured as a voltammetric or fluorescent output67. Glucose-binding 
moieties that have been used for such applications include natural molecules such as 
lectins67,68, synthetic molecules such as phenylboronic acid (PBA)69,70, and molecularly 
imprinted polymer hydrogels based on polyacrylamides63 and polyallylamines63,71. One of 
the most commonly used lectins for glucose sensing is concanavalin A (ConA), which is 
derived from the jack bean plant and binds specifically and reversibly to glucose72. Another 
is glucose-binding protein, a bacterial surface protein that undergoes a conformational 
change upon binding to glucose73. PBA is an organic molecule (FIG. 2a) that can reversibly 
bind to 1,2- or 1,3-cis-diols, such as glucose, to form cyclic esters74. When these moieties 
are associated with carbon nanotubes75,76 or nano-optodes77,78, they can potentially convert 
the binding event into a voltammetric output or cause a shift in fluorescence spectra. A 
major advantage of such devices is that they do not require a battery and may therefore 
function continually and for longer periods79.
Nanoparticles such as semiconducting quantum dots and single-walled carbon nanotubes are 
being developed as fluorescence-emitting components of such sensors74,79. In recent years, 
some of these formulations have been described in the literature75,80,81. Earlier versions 
utilized a glucose oxidase-based detector, which has a limited in vivo lifetime80. Other 
particles in development use sensing molecules such as PBA to improve in vivo fidelity and 
longevity75,76. When properly engineered, sensors based on carbon nanotubes have 
demonstrated remarkable longevity. For example, carbon nanotubes that were engineered as 
nitric oxide sensors and embedded in a biocompatible alginate gel matrix remained 
functional for more than 400 days when implanted subcutaneously into mice82. However, 
although these results are very promising, additional efforts towards improving the 
reliability of measurements may be needed before this approach can be translated into the 
clinic. Concerns remain regarding the safety of carbon nanotubes, which may be a barrier to 
their clinical translation83. Initial pilot studies in mice have suggested that when carbon 
nanotubes are properly engineered with hydrophilic and biocompatible coatings, their 
potential toxicity can be minimized84,85. However, the long-term safety profile of carbon 
nanotubes remains unknown. Another challenge associated with fluorescence glucose 
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nanosensors is the need for device biocompatibility as well as reliable calibration of 
fluorescent signals across multiple skin regions on a single patient, which can vary in colour, 
thickness and hair density86.
Owing to their small footprint, multiple nanosensors may be placed throughout the body to 
monitor blood glucose in parallel, reducing dependency on a single sensor and the risk of 
total sensor failure87. They may also be placed in more physiologically relevant locations, 
including in circulating blood or the lining of blood vessels, which would sample blood 
glucose directly, rather than in the subcutaneous interstitial fluid where current sensors are 
implanted53.
The development and testing of glucose nanosensors is at an early stage, with in vivo 
evaluation having only been carried out in animals so far. The non-enzymatic technologies 
that have been developed for nanosensors may be readily translated to and developed into 
next-generation continuous glucose-monitoring sensors with less variability than current 
glucose oxidase-based sensors. The non-invasive nanosensors with optical or fluorescent 
readouts hold the most promise to replace the current standard of manual glucose sensing 
based on finger pricking. Such optically based sensors have generated considerable interest 
because they do not require a battery or an enzyme-based catalyst and can be engineered to 
provide ultrafast readouts at rates that are significantly higher than current electrode-based 
sensors.
Insulin delivery
Nanotechnology is being used to improve the ease, efficacy and safety of insulin 
replacement therapy88,89. For example, long-acting nanoparticulate formulations of insulin 
have been developed to minimize the frequency of injections90. Since the first description of 
smart, glucose-responsive insulins in 1979 (REF. 91), there has been considerable interest in 
developing insulin formulations with activity that is dependent on glucose concentration, as 
this could facilitate tighter glycaemic control while minimizing the potential for 
hypoglycaemia92. In addition, new formulations are being explored to enable alternative, 
less invasive routes for insulin delivery (that is, oral93, transdermal94 and inhaled 
delivery95). Multifunctional nanoparticle formulations have the potential to address many of 
these challenges96. Insulin-delivering nanoparticle technology is rapidly maturing, and some 
early-generation carriers are in the clinic97. Here, we highlight the areas where 
nanotechnology has had an impact and holds substantial potential in improving the delivery 
of insulin.
Glucose sensor-dependent insulin delivery
As well as improving the reliability of detecting glucose levels, the sensors discussed above 
could be used as glucose-responsive insulin delivery systems. These delivery systems offer 
the potential to more accurately mimic the physiological response to changes in blood 
glucose levels and correspondingly modulate the kinetics of insulin release. Such 
improvements may provide tighter glycaemic control while minimizing the potential for 
hypoglycaemia. By combining advances in polymer engineering and nanotechnology, 
nanoparticle formulations can be engineered that can sense changes in their environment and 
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disassemble to release their cargo98 (FIG. 3). As noted above, the three most common 
glucose-sensing triggers are glucose oxidase, glucose-binding proteins and glucose-binding 
small molecules99 (FIG. 3a). Nanoparticle formulations using these glucose-responsive 
molecules can be engineered that detect environmental fluctuations in blood glucose levels 
and respond by releasing the insulin cargo through material degradation, disassembly or 
swelling100,101 (FIG. 3b).
As noted above, the specific enzymatic conversion of glucose to gluconic acid in biological 
environments (that is, in blood and urine)55 by glucose oxidase is the most prevalent of the 
various glucose-sensing mechanisms described in the literature102. One early example 
utilizing this mechanism involved pH-responsive insulin analogues that are insoluble at 
physiological pH but soluble under acidic conditions, allowing insulin release into the 
body103. When formulated with glucose oxidase and implanted in the body, hyperglycaemic 
conditions result in acidic microenvironments and insulin is therefore released to regulate 
blood glucose levels. More recently, material systems engineered to respond to acidic 
environments have been used as glucose-responsive platforms. For example, microgels 
composed of chitosan, glucose oxidase nanocapsules and insulin demonstrated glucose-
dependent release of insulin and control of blood glucose in animal models104. Polymeric 
nanoparticles have been developed that erode under acidic conditions to release insulin 
cargos105,106. Based on this principle, a glucose-mediated insulin-delivering nanonetwork 
formulation was developed107. Many of these strategies have demonstrated pulsatile insulin 
release in vitro in response to changing glucose concentrations and euglycaemia in rodents 
from 10 to 295 days after the administration of a single dose. However, glucose oxidase-
based systems can have slow and sometimes unpredictable response rates to changing 
glucose concentrations — due to changes in temperature or oxygen concentration — that 
subsequently affect the translation of a change in glucose concentration into a shift in pH.
Alternatively, efforts to develop non-enzymatic glucose-responsive materials and drug 
delivery systems have focused on the discovery of chemical moieties that specifically bind 
glucose. For example, glucose-binding moieties can be used as crosslinkers between 
polymers exhibiting glucose side chains, whereby free glucose competitively binds to the 
moiety to disrupt the crosslinks, leading to disassembly or swelling to release cargo108 (FIG. 
3b). One example involves the combination of glucose-modified insulin and the glucose-
binding lectin, ConA, as an injectable conjugate that dissociates under increased glucose 
concentrations91,109. Although the responsive system remains to be demonstrated in vivo, 
modified insulins exhibit comparable activity to native insulin in rodents. Indeed, ConA 
formulations have garnered interest because they bind glucose with high specificity and 
affinity. However, a major challenge has been to overcome host immunological responses to 
non-native ConA110. Despite the immunological concerns, there is still great interest in 
developing such systems for clinical use. In fact, in 2010 Merck made an investment to 
develop a lectin-based glucose-responsive nanoparticle technology named ‘Smart 
Insulin’111, which suggests there is growing industrial interest in glucose-responsive 
formulations. Reports from the company suggest that Phase I trials may soon be underway 
to evaluate L-490 (Smart Insulin) in patients with diabetes112.
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Small-molecule glucose binders such as PBA represent a chemical approach to glucose-
responsive insulin delivery. For example, PBA has been formulated to function similarly to 
glucose-binding proteins as a gel with glucose-decorated polymers. Such a system can act as 
a sol-gel crosslinker113,114. An increase in glucose concentration leads to a decrease in the 
crosslinking density, resulting in swelling or erosion to its soluble form113. As glucose 
concentration decreases, the glucose exchange is reversed, and the borate–diol crosslinking 
is re-established. Two challenges to the use of PBA lie in its lack of specificity for glucose, 
as it has a higher affinity for other diols in the body such as fructose, and its pKa of ~9, 
which precludes efficient binding to glucose at physiological pH74. Efforts are underway to 
develop PBA derivatives that can function under physiological pH with improved glucose 
specificity115,116.
In recent years, several stimuli-responsive nano-devices have been described to be capable 
of responding to changes in pH117, shear pressure118 and external stimuli (that is, light119, 
magnetic forces120 or ultrasonic waves121) to release drugs. For example, a nanonetwork of 
insulin with PLGA (poly(lactic-co-glycolic acid)) nanoparticles releases insulin at basal 
levels and releases a burst of insulin upon exposure to ultrasound121. As the field of 
nanotechnology matures, new opportunities may emerge for the development of insulin-
delivering nanodevices that better mimic the physiological needs of the patient.
In summary, the most evaluated approaches for developing glucose-responsive insulin 
delivery have been those based on glucose oxidase owing to its high specificity for glucose, 
its current usage in glucose sensors and the wide array of pH-responsive materials. 
However, the enzymatic conversion of glucose remains unreliable and slow, and the release 
of insulin from these nanoparticles is indirectly related to glucose concentration. Glucose-
binding proteins provide high specificity and binding to glucose; however, limited progress 
has been made towards eliminating the foreign body response. Small-molecule binders 
currently lack specificity for glucose but new approaches such as multiplexing PBAs are 
being investigated to address this concern.
Non-invasive delivery
The development of non-invasive methods for insulin administration has the potential to 
improve patient compliance and reduce complications associated with poor glycaemic 
control. Oral, inhalable and transdermal delivery can provide painless and simple methods 
relative to traditional insulin injections18. However, poor and unpredictable bioavailability 
has limited the success of insulin delivery via these alternative routes. This is due in part to 
the harsh environment of the gastrointestinal tract, variable and unpredictable inhalation 
efficiency, and limited transport across epithelial barriers93. Nanotechnology has been used 
to address these challenges and develop non-traditional delivery routes18 (FIG. 4).
The oral route is patient-friendly, as the ingestion of solid tablets or liquids is non-invasive 
and relatively discrete93. However, orally delivered insulin must survive the harsh 
enzymatic environment of the gut and be transported across the intestinal epithelial barrier 
before it can enter the bloodstream to have a glucose-lowering effect93. Nanoparticles have 
been used as protective carriers against enzymatic and hydrolytic degradation for various 
drugs, including insulin122. Transport across epithelial barriers can occur via passive (that is, 
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transcellular or paracellular) diffusion97,123, active transport (that is, receptor-mediated 
transport or involving membrane-derived vesicles and membrane-bound carriers)124, 
endocytosis (that is, adsorptive-mediated endocytosis and fluid-phase endocytosis)125 and 
Microfold cell (M cell) antigen sampling126. Formulations have been developed to stimulate 
paracellular transport127, and nanoparticles can be decorated with ligands to facilitate 
receptor-mediated transcytosis across epithelial barriers128. Recently, insulin-loaded 
polymeric PLGA nano-particles functionalized with Fc fragments on the surface were 
reported to target the neonatal Fc receptor in the intestinal epithelium128. When tested in 
vivo in mice, these Fc-fragment-decorated nanoparticles improved transport across the 
intestinal epithelium, resulting in a tenfold higher mean absorption efficiency compared to 
non-targeted nanoparticles128. Importantly, a biologically relevant insulin dose of 1.1 U per 
kg was able to reduce blood glucose levels in a healthy mouse, which indicates that the 
delivered insulin was biologically active and functional128. Although these findings are 
promising, the utility of oral insulin nanoparticles may be limited to replacing injections of 
long-acting insulin, whereas replacing fast-acting insulin will require more predictable 
insulin absorption profiles.
The airways, which have a large surface area, can also be used to deliver drugs, and offer the 
advantages of a relatively mild environment (neutral pH and low enzyme concentrations) 
compared to the gastrointestinal tract, as well as access to the underlying vascular and 
lymphatic systems129,130. Nanoparticle formulations have the potential to enhance inhaled 
drug delivery as a result of improved distribution in the airways, regulation of drug release 
rates, their ability to penetrate the mucosal barrier131 and transport across the epithelial 
barrier132. Inhaled insulin nanoparticles have demonstrated sustained insulin activity (18 
hours) over standard subcutaneous injections (2 hours) in diabetic rats133. Exubera, a dry 
powder inhaled insulin formulation developed by Pfizer and approved in 2006, provided the 
first non-injectable insulin option for patients with diabetes. Inhaled insulin offered similar 
bioactivity to subcutaneously injected fast-acting insulin134, but was ultimately withdrawn 
from the market owing to poor sales, which have been attributed to added costs, a bulky 
device and an FDA-imposed requirement that patients must undergo regular lung function 
tests to ensure they are receiving proper insulin bioavailability14,135,136. Recently, a more 
patient-friendly formulation, Afrezza (MannKind Corporation), received marketing approval 
from the FDA to improve glycaemic control in adults with type 2 diabetes137. Afrezza is an 
ultra-fast-acting inhalable insulin prepared as microspheres that is administered before 
meals. In clinical studies, it has been shown to lower glycated haemoglobin (HbA1c) levels 
in patients with type 1 and type 2 diabetes compared to standard treatment protocols138.
Alternatively, the transdermal route can be used to actively or passively transport 
nanomaterials through the skin for diabetes therapy. Transdermal drug delivery has the 
potential to facilitate sustained delivery of substantial payloads94. However, molecules that 
are large or hydrophilic, such as insulin, suffer from poor absorption owing to the very low 
permeability of the stratum corneum139. One approach has been to explore gold nanorods 
(27 × 66 nm in size) as vehicles to deliver insulin transdermally through a paracellular 
pathway140. In addition, permeation enhancers have enabled transdermal delivery of other 
nanoparticles141. Other approaches utilize a more active method, such as ultrasonication or 
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heat to locally increase the permeability of the skin in order to improve delivery142. In 
diabetic rodents, these systems have demonstrated blood glucose suppression for up to 10 
hours140 and peak insulin concentrations for around 4 hours143.
With the advent of novel routes of insulin delivery using nanoparticles, the safety and 
loading capacity of formulations must be considered. Insulin loading is typically poor in 
water-insoluble nanoparticles, with insulin representing a small percentage of the total 
formulation by weight128. As such, a substantial amount of material will need to be 
administered to achieve sufficient insulin delivery, and the formulation material will need to 
be suitably cleared following repeated dosing to allow for long-term treatment.
Non-insulin-based therapies
Cell-based therapy for diabetes involves the regeneration of β-cells, reprogramming of 
native cells to secrete insulin or the transplantation of insulin-producing cells to restore 
insulin production in response to glucose level changes144. The introduction of new insulin-
producing cells in the body can lead to a foreign body response and transplant rejection or 
generate an innate immune response against these cells; long-term protection against these 
responses is necessary to ensure the survival and function of transplanted insulin-producing 
cells144. Nanoparticles hold the potential to address some of these challenges.
Exogenous cell therapy, typically in the form of islet transplantation, was introduced as an 
approach to restore normoglycaemia in patients with type 1 diabetes in the early 1970s145. 
However, owing to host rejection of transplanted cells, limited amounts of donor cells and 
the extensive immunosuppressive therapy needed to address it, the clinical application of 
islet transplantation has been limited144. Over the past four decades, efforts have been made 
to develop an improved bioartificial pancreas that alleviates the need for immunosuppressive 
therapies146. Nanotechnology is now being developed for more advanced engineering of 
complex tissues22. For example, nanotechnology has been used to isolate and protect 
transplanted cells from the immune system while allowing sufficient diffusion of oxygen, 
glucose, insulin and other necessary nutrients147. Towards this goal, various conformal 
coating approaches, including layer-by-layer polymer deposition148, polyion complex 
formation149 and chemical reactions of polymers150, have been applied to islets to produce 
nano-thin coatings that may protect islet activity without inhibiting their function148. One 
barrier in translating these technologies to the clinic remains the lack of encapsulating 
materials that can avoid host recognition and subsequent foreign body responses151. Future 
advancement of islet encapsulation requires that materials and devices be developed such 
that encapsulated cells can maintain function and viability while avoiding fibrosis152.
Gene therapy to either express or silence specific genes involved in the immune response is 
an alternative strategy that circumvents the immune response to cell therapies153. 
Nanoparticles have been developed to protect and deliver nucleic acids to target cells154. For 
example, polymeric nanoparticles have been used to deliver DNA encoding interleukin-10 
(IL-10) and IL-4 to white blood cells to suppress the T cell response against remaining 
innate islet cells in animal models of early diabetes, preventing the development of diabetes 
in 75% of animals155. Alternatively, the gene encoding glucagon-like peptide 1 has been 
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delivered via nanoparticles to boost insulin secretion and islet viability156. One interesting 
example describes bioengineered cells containing SPIONs that have been demonstrated to 
produce insulin upon induction of hyperthermia through the external application of 
alternating magnetic currents. In this study, it was demonstrated that the cells were able to 
generate insulin on demand in vivo to regulate blood glucose levels120. Although the 
complexity of this specific system may delay its clinical translation, the concept of using 
non-invasive external triggers to regulate insulin production and release is exciting and 
opens new opportunities for engineering an automated synthetic pancreas device.
Finally, vaccines have been investigated as a long-term strategy to prevent the autoimmune 
destruction of β-cells in patients with type 1 diabetes. Nanotechnology in general has been 
used to improve the development of vaccines for a number of diseases157. It has been shown 
to alleviate the need for antigen adjuvants158 and can direct antigens to specific sites of the 
body159. Nanotechnology can also improve the potency of antigens160, provide a physical 
platform for the use of combinations of antigens161 and enable the delivery of self-
replicating and RNA-based antigens162,163. Specifically, diabetes vaccine development 
efforts have focused on blunting the cytotoxic T cell immune response against β-cells 
without compromising global immunity5. Using a non-obese diabetic mouse model, 
magnetic nanoparticles coated with appropriate peptide-major histocompatibility complexes 
(pMHC–NPs) were shown to expand a population of naive low-avidity autoreactive CD8+ T 
cells into memory-like autoregulatory cells, to prevent and reverse type 1 diabetes in 75% of 
mice164.
Conclusions and outlook
The development of nanotechnology for the management of diabetes has only recently 
begun, but is occurring at a rapid pace owing to inspiration and adaptation from successes in 
treatments for other diseases. These include cancer165–167, for which the first nanoparticle-
based therapy, a pegylated liposome nanoparticle formulation loaded with the 
chemotherapeutic agent doxorubicin, received FDA approval in 1995 (REF. 168). Since 
then, the pipeline of nanomedicines for cancer indications has expanded considerably, with 
more than 20 different formulations currently under clinical investigation169. 
Nanotechnology has also been developed for the management of cardiovascular 
disease170,171; for example, nanoparticles have been used to deliver MRI contrast agents for 
the monitoring of acute myocardial infraction in human patients172. As a result, there is 
already an extensive toolbox of promising and clinically applicable nanotechnology-based 
formulations173.
Non-invasive monitoring of disease progression and blood glucose levels, glucose-
responsive and patient-friendly insulin, and improved immune modulation for cell-based 
therapies are among the advances developed to date. However, the bar for success is high, as 
diabetes management is well established with advanced control algorithms using continuous 
glucose monitors and insulin pumps in outpatient clinical studies13. The long-term safety of 
nanotechnology is also under increased scrutiny173. Indeed, the FDA recently issued 
guidance to help foster the safe development of nanotechnology-based products for clinical 
use174. Safety and long-term performance must be fully evaluated in the design of diabetes 
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therapeutics and diagnostics, especially for materials that are not degraded or cleared from 
the body.
We envision promising opportunities in the development of closed-loop glucose sensing and 
insulin-delivering nanoparticle formulations. Further development of new glucose-sensing 
molecules that can serve as triggering mechanisms for both sensors and glucose-responsive 
materials will be key to the advancement of this technology. The next generation of 
nanosensors and integrated glucose-mediated insulin delivery formulations will need to 
demonstrate increased sensitivity and specificity to glucose. Specifically, a major challenge 
remains with prolonged lag times for response to increased blood glucose levels. A potential 
solution may rest in the development of new glucose-responsive moieties with stronger 
association constants, as well as materials containing these binding domains. The next 
generation of glucose sensor technologies will need to be more consistent and reliable, with 
less drift resulting from sensor degradation or failure. A tight coupling between glucose 
sensing and insulin delivery is needed to effectively control blood glucose. The 
implementation of glucose-mediated insulin-delivering technologies into the clinical setting 
will probably hinge on innovations that help to reduce the lag between sensing and 
therapeutic delivery, as well as increasing the response rate to changes in glucose levels.
Cell-based therapy is another area in which nanotechnology may have an important role in 
reducing the immune response to the new insulin-producing cells. Nanoparticles show 
considerable promise as agents for delivering nucleic acid therapeutics175, and advances are 
likely to be made with the development of improved cellular targeting strategies. These may 
be useful in therapies that involve the reprogramming of endogenous cells into islet-like 
cells, as well as in the development of transplanted islets176.
In summary, we expect nanotechnology to play an important part in improving the 
management of diabetes within the next decade. The emergence of FDA-approved 
nanotechnology formulations coupled with the clinical success of insulin-delivering 
technologies through the pulmonary route is encouraging. In our view, the greatest need and 
also the highest clinical potential for nanotechnology-based diabetes therapy lies in the 
development of robust glucose-sensitive nanoparticles and nanodevices for integration into 
sensors, and the development of integrated glucose-sensing and insulin-delivering 
nanoformulations.
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Glossary
Hyperglycaemia A condition of high blood glucose levels, typically >200mg/dL
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Insulin A peptide hormone that is produced by β-cells in the pancreas. 
It regulates the metabolism of carbohydrates and fats and 
reduces blood glucose by promoting the absorption of glucose 
from blood to skeletal muscles and fat tissue
β-cells Cells in the pancreas that are located in the islets of Langerhans 
and that store and secrete insulin
Hypoinsulinaemia A condition of abnormally low concentrations of insulin in the 
blood
Hypoglycaemia A condition of low blood glucose levels, typically <70mg/dL
Glucagon A peptide hormone that is produced by α-cells in the pancreas 
and raises blood glucose levels
Open loop A form of insulin replacement therapy whereby the required 
insulin levels are empirically estimated by blood glucose 
measurement and meal intake and insulin is injected by the 
patient at different times throughout the day
Magnetic resonance 
imaging (MRI)
Imaging technique by which strong magnetic fields are applied 
to the area of interest, exciting hydrogen atoms to emit a radio 
frequency signal, which is then captured. T1 (spin-lattice) and 
T2 (relaxation) processes can be captured to assess different 
types of tissue
Inflammation Biological response of tissues to harmful stimuli, such as 
foreign objects and dead cells
Glucose oxidase An enzyme that catalyses the oxidation of glucose into 
hydrogen peroxide and D-glucono-δ-lactone
Amperometric Relating to the measurement of changes in electrical current of 
an electrode with an applied voltage in response to the presence 
of an analyte
Carbon nanotubes Allotrope of carbon that takes a cylindrical shape
Voltammetric A subset of amperometry, where the applied voltage is 
additionally varied
Phenylboronic acid (PBA). Mild Lewis acid that binds reversibly to 1,2- and 1,3-
diols, such as glucose
Sol-gel crosslinker A reversible interaction that switches the properties of the bulk 
material from solution (sol) to a network (gel) phase
PLGA (poly(lactic-co-
glycolic acid)
A biodegradable copolymer used in a number of US Food and 
Drug Administration (FDA) approved therapeutic devices, 
including nanoparticles and sutures
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Bioavailability The fraction of an administered dosage that reaches systemic 
circulation, where 100% is defined by intravenous injection
Microfold cell (M cell) A cell that is found in the epithelium of Peyer’s patches in the 
intestines and that facilitates uptake of antigens
Fc receptor Cell surface protein that is found on the surface of many cell 
types and mediates binding of the Fc region of antibodies
Interleukin Class of cytokines that are expressed by white blood cells and 
promote the development of T lymphocytes and B lymphocytes
Closed-loop A form of insulin replacement therapy whereby the required 
insulin is automatically determined and the proper insulin 
dosage is delivered with minimal patient involvement
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Figure 1. Nanotechnology-based approaches to address challenges in the diagnosis and 
treatment of diabetes
a | The progression of diabetes results in a loss in β-cell mass, which can be subcategorized 
into three stages: primary, secondary and tertiary. As the disease progresses through each 
stage, new types of therapies are necessary to help slow advancement to the subsequent 
stage. b | Highlighted below the profile illustrating the progressive loss in β-cell mass are 
potential nanotechnology-based interventions that could be developed to address patient 
needs at the various stages of disease progression. A number of examples are highlighted, 
including: nanoparticle-based contrast agents to improve early diagnosis of the onset of type 
1 diabetes; nanoparticle-based continuous glucose sensors that can facilitate frequent 
monitoring of blood glucose levels with improved accuracy and patient comfort; 
nanoparticles to improve the pharmacodynamics of insulin in order to better mimic the 
physiological needs of the body; and nanotechnology-based protection of transplanted 
pancreatic islet cells. These approaches can be used as highlighted to help maintain healthy 
normoglycaemic levels in patients with diabetes.
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Figure 2. Nanotechnology-based glucose sensor technologies
Sensing devices are constructed by assembling a detector that measures blood glucose 
concentrations and a transducer that converts measurements into output signals. a | There are 
three main classes of glucose-sensing molecules that are being used to engineer 
nanoparticle-based glucose sensors: glucose oxidase, glucose-binding proteins and glucose-
binding small molecules. Highlighted next to the description of each detection molecule are 
the strengths (green boxes) and weaknesses (red boxes) associated with each technology. b | 
These glucose-detecting molecules can be coupled to nanoparticles engineered as 
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transducers with unique optical or electrical properties, as well as the ability to produce 
surface plasmon resonance. The strengths (green boxes) and weaknesses (red boxes) 
associated with each technology are shown. ConA, concanavilin A; hv, excitation light; IR, 
infrared; PBA, phenylboronic acid.
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Figure 3. Development of glucose-responsive
a | There are several mechanisms by which glucose-sensing triggers can be integrated with 
nanoparticle design to facilitate glucose-responsive behaviour. Nanoparticles prepared using 
polymers that are molecularly imprinted with glucose and phenylboronic acid (PBA) could 
form supramolecular assemblies through reversible hydrogen-bonding interactions between 
glucose and PBA molecules. These nanoparticle assemblies would then be sensitive to 
glucose concentrations in their localized environment through the competitive binding of 
glucose from the environment to PBA. Alternatively, glucose-imprinted polymers could be 
combined with glucose-binding proteins such as concanavilin A (ConA) to form 
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supramolecular assemblies that are similarly responsive to glucose. Glucose-sensitive 
nanoparticle systems can also be engineered by combining pH-sensitive polymers with the 
glucose-sensitive enzyme glucose oxidase, which enzymatically converts glucose to 
gluconic acid, producing a drop in pH in the nanoparticle microenvironment. b | The triggers 
can be integrated within a nanoparticle that is engineered to disassemble by either swelling 
or degrading in response to increased glucose levels, thus providing a mechanism by which 
the insulin cargo can be released and made bioavailable.
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Figure 4. Development of patient-friendly insulin delivery nanoparticle formulations
Various properties of nanoparticles can be tailored to exploit transepithelial transport 
mechanisms to facilitate systemic insulin delivery. Nanoparticles prepared with bound 
ligands for specialized receptors expressed on epithelial cell surfaces can be transcytosed 
across epithelial barriers. Ultrasmall nanoparticles with hydrophilic coatings can exploit 
paracellular diffusion to bypass epithelial barriers. Nanoparticles with tuned lipophilic 
physicochemical properties can permeate across epithelial barriers through a transcellular 
pathway. Cationic charged nanoparticles can exploit the adsorption-mediated transcytosis 
pathway for transport across epithelial barriers. Finally, nanoparticles that are transported 
across epithelial barriers by antigen sampling Microfold cells (M cells) could be developed.
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